10x Genomics Acquires Proteintech Genomics to Enhance Proteomics Capabilities
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 09 2026
0mins
Source: seekingalpha
- Acquisition Context: 10x Genomics has acquired the genomics division of Proteintech Group to expand its proteomics capabilities, and while the financial terms of the deal remain undisclosed, this move underscores the company's commitment to technological integration.
- Technological Edge: Proteintech Genomics brings its Human Discovery Panel, touted as the largest antibody-based single-cell protein panel, designed to support integrated analysis of intracellular proteins, cell surface proteins, and transcriptomic profiles, thereby enhancing 10x Genomics' product offerings.
- Financial Impact: 10x Genomics stated that the acquisition is not expected to materially impact its near-term financial outlook, indicating a robust financial strategy while pursuing technological advancements.
- Market Strategy: This acquisition not only strengthens 10x Genomics' competitive position in the proteomics field but also lays the groundwork for future product development and market expansion, further solidifying its leadership in the genomics sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TXG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TXG
Wall Street analysts forecast TXG stock price to fall
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 32.130
Low
9.00
Averages
13.00
High
18.00
Current: 32.130
Low
9.00
Averages
13.00
High
18.00
About TXG
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IQM Quantum Computers Appoints New Executives Ahead of Nasdaq Listing
- Executive Appointments: IQM Quantum Computers has appointed Craig Ciesla as Chief Technology Officer and Inés de Vega as Chief Scientist, aiming to strengthen the company's technological leadership in preparation for its upcoming Nasdaq listing.
- Technology Strategy Advancement: With over 25 years of experience in deep tech, Ciesla will be responsible for driving the implementation of IQM's technology strategy, playing a crucial role in accelerating the development of fault-tolerant quantum computing.
- Market Leadership: Having sold 23 quantum computers, IQM has established itself as a leader in superconducting quantum computing, and Ciesla's addition is expected to further solidify its market position in high-performance computing.
- Funding Progress: As the merger with Real Asset Acquisition Corp. advances, IQM successfully completed a $146 million PIPE financing in June, reflecting strong market confidence in its future growth.
See More
10x Genomics Collaborates with Cleveland Clinic on Bladder Cancer Research
- Collaboration Initiated: 10x Genomics has partnered with Cleveland Clinic to leverage its single-cell and spatial platforms to identify biomarkers predictive of bladder cancer patients' responses to antibody-drug conjugate (ADC) treatments, advancing novel diagnostics.
- Multi-Platform Application: The study will initially analyze tumor samples from patients with advanced bladder cancer undergoing emerging therapeutic regimens using the Flex Apex and Xenium platforms, with plans to expand to the newly announced Atera platform, aiming to generate a comprehensive multimodal dataset for clinical applications.
- Biomarker Exploration: The research will integrate single-cell transcriptomic profiling, spatial gene expression, and protein measurements to better understand tumor microenvironment composition, immune cell infiltration, and therapeutic target expression, revealing mechanisms of treatment response and resistance.
- Significant Scientific Implications: This collaboration is expected to provide new insights into the reasons behind differential patient responses to the same therapy, driving innovation in diagnostic approaches within oncology and addressing the urgent clinical need for personalized treatment strategies.
See More
Regentis Soars After Withdrawing US Listing Application
- Regentis Stock Surge: Regentis Biomaterials Ltd. (RGNT) saw its shares soar over 500% to close at $9.40 after withdrawing its Form F-1 registration with the SEC, indicating strong market confidence in its strategic decision.
- GelrinC Product Development: The company's lead product, GelrinC, has received CE Mark approval in Europe, with plans to initiate surgeon training in Q3 2026, which is expected to enhance its market readiness and competitive positioning.
- Cuprina FDA Approval: Cuprina Holdings (CUPR) received FDA clearance for its MEDIFLY maggots used in wound debridement therapy, leading to a stock increase of over 100%, reflecting its innovative potential and market demand in the medical field.
- Intellia Positive Results: Intellia Therapeutics (NTLA) jumped over 20% following positive phase 3 results for its hereditary angioedema treatment, with plans for a BLA submission targeting FDA approval in the first half of 2027, showcasing its strong prospects in the biopharmaceutical sector.
See More
10x Genomics Acquires Proteintech Genomics to Enhance Proteomics Capabilities
- Acquisition Context: 10x Genomics has acquired the genomics division of Proteintech Group to expand its proteomics capabilities, and while the financial terms of the deal remain undisclosed, this move underscores the company's commitment to technological integration.
- Technological Edge: Proteintech Genomics brings its Human Discovery Panel, touted as the largest antibody-based single-cell protein panel, designed to support integrated analysis of intracellular proteins, cell surface proteins, and transcriptomic profiles, thereby enhancing 10x Genomics' product offerings.
- Financial Impact: 10x Genomics stated that the acquisition is not expected to materially impact its near-term financial outlook, indicating a robust financial strategy while pursuing technological advancements.
- Market Strategy: This acquisition not only strengthens 10x Genomics' competitive position in the proteomics field but also lays the groundwork for future product development and market expansion, further solidifying its leadership in the genomics sector.
See More
10x Genomics CEO Serge Saxonov Sells Shares in Open-Market Transactions
- Transaction Overview: 10x Genomics CEO Serge Saxonov sold 28,893 shares of common stock in multiple open-market transactions between May 22 and May 26, 2026, with an aggregate transaction value of approximately $709,000, indicating his active engagement in the market.
- Historical Comparison: This sale marks Saxonov's largest single open-market transaction in the past two years, exceeding his previous maximum sale of 16,152 shares, suggesting a significant increase in his selling scale that could impact future sale capacity.
- Ownership Changes: Following the sale, Saxonov's direct ownership decreased to 1,138,380 shares, while his total position, including indirect holdings through family trusts, remains at 1,423,301 shares, indicating he still retains substantial control over the company.
- Investor Confidence Maintained: Despite a 3% year-over-year decline in first-quarter revenue to $150.8 million, the company managed to reduce its net loss to $13.5 million, showcasing resilience in the market and maintaining investor optimism regarding its future growth prospects.
See More
10x Genomics CEO Sells $709,000 in Shares Amid Strong Stock Performance
- Executive Share Sale: 10x Genomics CEO Serge Saxonov sold 28,893 shares of common stock between May 22 and May 26, 2026, for approximately $709,000, demonstrating executive liquidity management amid stock performance.
- Stable Holdings: Despite the sale, Saxonov retains over 1.4 million shares in direct and indirect holdings, indicating his confidence in the company's future and commitment to ongoing investment.
- Compliance in Trading: The share sale was executed under a Rule 10b5-1 trading plan established in November 2025, aimed at avoiding insider trading allegations, showcasing the company's governance transparency and compliance.
- Improved Financial Performance: Although 10x Genomics reported a 3% year-over-year revenue decline to $150.8 million in Q1, effective cost management reduced net losses to $13.5 million, reflecting the company's ability to maintain profitability in challenging conditions.
See More
IQM Quantum Computers Appoints New Executives Ahead of Nasdaq Listing
- Executive Appointments: IQM Quantum Computers has appointed Craig Ciesla as Chief Technology Officer and Inés de Vega as Chief Scientist, aiming to strengthen the company's technological leadership in preparation for its upcoming Nasdaq listing.
- Technology Strategy Advancement: With over 25 years of experience in deep tech, Ciesla will be responsible for driving the implementation of IQM's technology strategy, playing a crucial role in accelerating the development of fault-tolerant quantum computing.
- Market Leadership: Having sold 23 quantum computers, IQM has established itself as a leader in superconducting quantum computing, and Ciesla's addition is expected to further solidify its market position in high-performance computing.
- Funding Progress: As the merger with Real Asset Acquisition Corp. advances, IQM successfully completed a $146 million PIPE financing in June, reflecting strong market confidence in its future growth.
See More
10x Genomics Collaborates with Cleveland Clinic on Bladder Cancer Research
- Collaboration Initiated: 10x Genomics has partnered with Cleveland Clinic to leverage its single-cell and spatial platforms to identify biomarkers predictive of bladder cancer patients' responses to antibody-drug conjugate (ADC) treatments, advancing novel diagnostics.
- Multi-Platform Application: The study will initially analyze tumor samples from patients with advanced bladder cancer undergoing emerging therapeutic regimens using the Flex Apex and Xenium platforms, with plans to expand to the newly announced Atera platform, aiming to generate a comprehensive multimodal dataset for clinical applications.
- Biomarker Exploration: The research will integrate single-cell transcriptomic profiling, spatial gene expression, and protein measurements to better understand tumor microenvironment composition, immune cell infiltration, and therapeutic target expression, revealing mechanisms of treatment response and resistance.
- Significant Scientific Implications: This collaboration is expected to provide new insights into the reasons behind differential patient responses to the same therapy, driving innovation in diagnostic approaches within oncology and addressing the urgent clinical need for personalized treatment strategies.
See More
Regentis Soars After Withdrawing US Listing Application
- Regentis Stock Surge: Regentis Biomaterials Ltd. (RGNT) saw its shares soar over 500% to close at $9.40 after withdrawing its Form F-1 registration with the SEC, indicating strong market confidence in its strategic decision.
- GelrinC Product Development: The company's lead product, GelrinC, has received CE Mark approval in Europe, with plans to initiate surgeon training in Q3 2026, which is expected to enhance its market readiness and competitive positioning.
- Cuprina FDA Approval: Cuprina Holdings (CUPR) received FDA clearance for its MEDIFLY maggots used in wound debridement therapy, leading to a stock increase of over 100%, reflecting its innovative potential and market demand in the medical field.
- Intellia Positive Results: Intellia Therapeutics (NTLA) jumped over 20% following positive phase 3 results for its hereditary angioedema treatment, with plans for a BLA submission targeting FDA approval in the first half of 2027, showcasing its strong prospects in the biopharmaceutical sector.
See More
10x Genomics Acquires Proteintech Genomics to Enhance Proteomics Capabilities
- Acquisition Context: 10x Genomics has acquired the genomics division of Proteintech Group to expand its proteomics capabilities, and while the financial terms of the deal remain undisclosed, this move underscores the company's commitment to technological integration.
- Technological Edge: Proteintech Genomics brings its Human Discovery Panel, touted as the largest antibody-based single-cell protein panel, designed to support integrated analysis of intracellular proteins, cell surface proteins, and transcriptomic profiles, thereby enhancing 10x Genomics' product offerings.
- Financial Impact: 10x Genomics stated that the acquisition is not expected to materially impact its near-term financial outlook, indicating a robust financial strategy while pursuing technological advancements.
- Market Strategy: This acquisition not only strengthens 10x Genomics' competitive position in the proteomics field but also lays the groundwork for future product development and market expansion, further solidifying its leadership in the genomics sector.
See More
10x Genomics CEO Serge Saxonov Sells Shares in Open-Market Transactions
- Transaction Overview: 10x Genomics CEO Serge Saxonov sold 28,893 shares of common stock in multiple open-market transactions between May 22 and May 26, 2026, with an aggregate transaction value of approximately $709,000, indicating his active engagement in the market.
- Historical Comparison: This sale marks Saxonov's largest single open-market transaction in the past two years, exceeding his previous maximum sale of 16,152 shares, suggesting a significant increase in his selling scale that could impact future sale capacity.
- Ownership Changes: Following the sale, Saxonov's direct ownership decreased to 1,138,380 shares, while his total position, including indirect holdings through family trusts, remains at 1,423,301 shares, indicating he still retains substantial control over the company.
- Investor Confidence Maintained: Despite a 3% year-over-year decline in first-quarter revenue to $150.8 million, the company managed to reduce its net loss to $13.5 million, showcasing resilience in the market and maintaining investor optimism regarding its future growth prospects.
See More
10x Genomics CEO Sells $709,000 in Shares Amid Strong Stock Performance
- Executive Share Sale: 10x Genomics CEO Serge Saxonov sold 28,893 shares of common stock between May 22 and May 26, 2026, for approximately $709,000, demonstrating executive liquidity management amid stock performance.
- Stable Holdings: Despite the sale, Saxonov retains over 1.4 million shares in direct and indirect holdings, indicating his confidence in the company's future and commitment to ongoing investment.
- Compliance in Trading: The share sale was executed under a Rule 10b5-1 trading plan established in November 2025, aimed at avoiding insider trading allegations, showcasing the company's governance transparency and compliance.
- Improved Financial Performance: Although 10x Genomics reported a 3% year-over-year revenue decline to $150.8 million in Q1, effective cost management reduced net losses to $13.5 million, reflecting the company's ability to maintain profitability in challenging conditions.
See More
